Synlogic Inc. (0A8U)

Overview

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focusing on the innovation and development of synthetic biotics for the treatment of metabolic and immunological diseases within the United States. Leveraging cutting-edge science to design its groundbreaking therapies, Synlogic is at the forefront of a new wave of medical treatments. Their work centers on designing uniquely engineered bacteria to perform specific therapeutic functions, proving a novel approach to treating a variety of conditions. The company has established strategic collaborations with renowned institutions like F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., alongside Ginkgo Bioworks, Inc., aiming to expand its research capabilities and accelerate the development of its synthetic biotic medicines for a range of diseases, including inflammatory bowel disease.

Products and Services

• SYNB1618 - An orally administered, non-systemically absorbed drug candidate designed for the treatment of phenylketonuria. Unlike traditional treatments, SYNB1618 operates within the gut to degrade phenylalanine, potentially offering a novel therapeutic option for patients with this metabolic disorder.
• SYNB1934 - This product is another orally administered, non-systemically absorbed drug candidate, currently in Phase III clinical trials, aimed at treating phenylketonuria. Representing an advancement in the treatment landscape, SYNB1934 illustrates Synlogic's commitment to addressing unmet needs in metabolic diseases through innovative therapies.
• SYNB1353 - Focused on treating homocystinuria, SYNB1353 is in Phase II clinical trials. This orally administered drug candidate does not get absorbed into the system, aiming to reduce homocysteine levels in the gut, thereby potentially mitigating the consequences of this rare but serious genetic disorder.
• SYNB8802 - In Phase II clinical trials for the treatment of enteric hyperoxaluria, SYNB8802 is an orally administered, non-systemically absorbed candidate. By targeting the gut environment to reduce the absorption of oxalate, this innovative approach could present a new treatment avenue for patients struggling with kidney stones and other complications resulting from high oxalate levels.
• SYNB2081 - Currently being developed to lower uric acid as a potential treatment for gout, SYNB2081 underscores Synlogic’s expansive aim to tackle a broad spectrum of metabolic conditions using synthetic biotics.
• SYNB1891 - A departure from the aforementioned orally administered treatments, SYNB1891 is designed for intratumoral delivery, targeting the treatment of solid tumors and lymphoma. This synthetic biotic medicine represents a pioneering approach to cancer treatment, leveraging the potential of engineered bacteria to stimulate an immune response against cancer cells.